Payment overview · 2025
General Payments
$445.70
18 reported records · 8 companies
Healthcare provider profile · identity verified
Mathew J Bauerle, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PUNTA GORDA, FL · NPI 1154790384
Verified facts
What the public records show
CMS Open Payments records show Mathew J Bauerle, ARNP received $445.70 in general payments during 2025 across 18 reported records.
Astellas Pharma US Inc accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $142.95 | 32.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.60 | 24.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.48 | 16.0% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $37.26 | 8.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.93 | 5.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.46 | 5.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.19 | 4.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.83 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $376.71 | 17 |
| Education | $68.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $78.41 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $73.96 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.10 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $37.26 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.38 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 95 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 695 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 423 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 379 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 332 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 302 | 93 |
| Alprazolam | Alprazolam | 260 | 61 |
| Mounjaro | Tirzepatide | 244 | 37 |
| Prednisone | Prednisone | 205 | 140 |
| Gabapentin | Gabapentin | 192 | 82 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 191 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 172 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 83 |
| Montelukast Sodium | Montelukast Sodium | 168 | 60 |
| Omeprazole | Omeprazole | 160 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 50 |
| Furosemide | Furosemide | 144 | 52 |
| Tramadol Hcl | Tramadol Hcl | 144 | 41 |
| Famotidine | Famotidine | 142 | 59 |
| Potassium Chloride | Potassium Chloride | 138 | 51 |
| Losartan Potassium | Losartan Potassium | 123 | 40 |
| Eliquis | Apixaban | 120 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 33 |
| Meloxicam | Meloxicam | 111 | 35 |
| Ozempic | Semaglutide | 110 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 38 |
| Lisinopril | Lisinopril | 107 | 32 |
| Clonazepam | Clonazepam | 102 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 33 |
| Trazodone Hcl | Trazodone Hcl | 100 | 32 |
| Jardiance | Empagliflozin | 98 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 32 |
| Azithromycin | Azithromycin | 95 | 70 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 95 | 25 |
| Valsartan | Valsartan | 93 | 29 |
| Methylprednisolone | Methylprednisolone | 87 | 79 |
| Sertraline Hcl | Sertraline Hcl | 79 | 22 |
| Atenolol | Atenolol | 78 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 43 |
| Fluconazole | Fluconazole | 69 | 46 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 68 | 57 |
| Pregabalin | Pregabalin | 68 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 23 |
| Spironolactone | Spironolactone | 67 | 21 |
| Fenofibrate | Fenofibrate | 63 | 17 |
| Alendronate Sodium | Alendronate Sodium | 61 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 29 |
| Xarelto | Rivaroxaban | 60 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 59 | 17 |
| Celecoxib | Celecoxib | 58 | 24 |
| Glimepiride | Glimepiride | 58 | 17 |
| Cephalexin | Cephalexin | 56 | 40 |
| Enalapril Maleate | Enalapril Maleate | 56 | 13 |
| Carvedilol | Carvedilol | 54 | 17 |
| Donepezil Hcl | Donepezil Hcl | 53 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 53 | 17 |
| Metformin Hcl Er | Metformin Hcl | 52 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 51 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 15 |
| Telmisartan | Telmisartan | 51 | 15 |
| Levofloxacin | Levofloxacin | 50 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 14 |
| Cefdinir | Cefdinir | 49 | 41 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 42 |
| Linzess | Linaclotide | 46 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 15 |
| Bupropion Xl | Bupropion Hcl | 43 | 18 |
| Finasteride | Finasteride | 43 | 12 |
| Ondansetron Odt | Ondansetron | 43 | 22 |
| Allopurinol | Allopurinol | 42 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 42 | 13 |
| Lorazepam | Lorazepam | 42 | 16 |
| Baclofen | Baclofen | 40 | 25 |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 19 |
| Eszopiclone | Eszopiclone | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 38 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 17 |
| Estradiol | Estradiol | 35 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 16 |
| Diazepam | Diazepam | 34 | 17 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Temazepam | Temazepam | 31 | suppressed |
| Dexamethasone | Dexamethasone | 30 | 25 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Armodafinil | Armodafinil | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Mupirocin | Mupirocin | 27 | 22 |
| Motegrity | Prucalopride Succinate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 19 |
| Metformin Hcl | Metformin Hcl | 25 | 12 |
| Mirtazapine | Mirtazapine | 25 | 16 |
| Digoxin | Digoxin | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 20 | 20 |
| Ramipril | Ramipril | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Azelastine Hcl | Azelastine Hcl | 19 | 11 |
| Dupixent Pen | Dupilumab | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Otezla | Apremilast | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Olanzapine | Olanzapine | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Rexulti | Brexpiprazole | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Simvastatin | Simvastatin | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Neupro | Rotigotine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.70 · 18 records | Astellas Pharma US Inc | EVENITY, Korlym, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, Sunosi, TRELEGY ELLIPTA, TZIELD, UBRELVY, Veozah, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error